BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34935688)

  • 1. Antibody-drug conjugates in HER2-positive breast cancer.
    Li L; Zhang D; Liu B; Lv D; Zhai J; Guan X; Yi Z; Ma F
    Chin Med J (Engl); 2021 Dec; 135(3):261-267. PubMed ID: 34935688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.
    Najminejad Z; Dehghani F; Mirzaei Y; Mer AH; Saghi SA; Abdolvahab MH; Bagheri N; Meyfour A; Jafari A; Jahandideh S; Gharibi T; Amirkhani Z; Delam H; Mashatan N; Shahsavarani H; Abdollahpour-Alitappeh M
    Mol Ther; 2023 Jul; 31(7):1874-1903. PubMed ID: 36950736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
    Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
    Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
    Abelman RO; Medford A; Spring L; Bardia A
    Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low.
    Fan P; Xu K
    Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188849. PubMed ID: 36502928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
    Pegram MD; Miles D; Tsui CK; Zong Y
    Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
    Pondé N; Aftimos P; Piccart M
    Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.
    Li XF; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(17):3339-3360. PubMed ID: 32900344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.
    Duro-Sánchez S; Nadal-Serrano M; Lalinde-Gutiérrez M; Arenas EJ; Bernadó Morales C; Morancho B; Escorihuela M; Pérez-Ramos S; Escrivá-de-Romaní S; Gandullo-Sánchez L; Pandiella A; Esteve-Codina A; Rodilla V; Dijcks FA; Dokter WHA; Cortés J; Saura C; Arribas J
    Cancer Res; 2022 Dec; 82(24):4670-4679. PubMed ID: 36222720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.
    McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
    Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
    Nicolò E; Zagami P; Curigliano G
    Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress.
    Chu Y; Zhou X; Wang X
    J Hematol Oncol; 2021 Jun; 14(1):88. PubMed ID: 34090506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current Progress and Future Developments of Antibody Drug Conjugates 
in Lung Cancer].
    Zhu Y; Wang Z
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):468-476. PubMed ID: 35899443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates in solid tumors: a look into novel targets.
    Criscitiello C; Morganti S; Curigliano G
    J Hematol Oncol; 2021 Jan; 14(1):20. PubMed ID: 33509252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.